Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers

被引:0
|
作者
Malo, Sara [1 ]
Aguilar-Palacio, Isabel [1 ]
Feja, Cristina [1 ]
Menditto, Enrica [2 ]
Jesus Lallana, Maria [3 ]
Andrade, Elena [4 ,5 ]
Antonio Casasnovas, Jose [6 ]
Jose Rabanaque, Maria [1 ]
机构
[1] Univ Zaragoza, Dept Med Prevent & Salud Publ, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
[2] Univ Napoli Federico II, CIRFF, Naples, Italy
[3] IIS Aragon, Serv Aragones Salud, Zaragoza, Spain
[4] Univ Autonoma Madrid, Dept Med Prevent & Salud Publ, IdiPaz, Madrid, Spain
[5] CIBERESP, Madrid, Spain
[6] Univ Zaragoza, Dept Med Psiquiatria & Dermatol, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2018年 / 71卷 / 01期
关键词
Discontinuation; Lipid-lowering drug; Pharmacoepidemiology; Medication; Measurement; Cardiovascular disease; Primary prevention; DENSITY-LIPOPROTEIN CHOLESTEROL; THERAPY; POPULATION; RISK;
D O I
10.1016/j.recesp.2017.03.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: The aim of this study was to assess patterns of treatment persistence in a cohort of male Spanish workers receiving statin therapy for primary prevention of cardiovascular disease. Methods: This descriptive study was conducted within the framework of the prospective longitudinal Aragon Workers' Health Study (N = 5400). Incident male statin users were identified based on data collected from the regional government's medication consumption information system. Patterns of treatment persistence with statins prescribed for primary cardiovascular disease prevention were assessed and, the relevance of potential predictors explored. Results: Among the 725 new statin users, less than one third remained persistent during the 1 year of follow-up. About 15% of nonpersistent users discontinued statin therapy after dispensation of the first prescription; of these, 42.1% did not recommence treatment within the following year. Factors reducing the likelihood of treatment discontinuation were older age (HR, 0.55; 95%CI, 039-0.77) and cotreatment with antihypertensive drugs (HR, 0.68; 95%CI, 0.56-0.82). No association was observed between treatment persistence and cotreatment with antidiabetic or antithrombotic drugs, baseline low-density lipoprotein levels, or total cholesterol levels. However, persistence was influenced by the type of statin first prescribed. Conclusions: Our analysis of a cohort of healthy male workers revealed poor statin persistence. These findings underscore the need for a better understanding of patterns of statin use, especially in apparently healthy individuals, and for the incorporation of patient behavior into prescribing decisions. (C) 2017 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 50 条
  • [1] Statins in primary prevention of cardiovascular disease
    Adham, S.
    Miranda, S.
    Doucet, J.
    Levesque, H.
    Benhamou, Y.
    REVUE DE MEDECINE INTERNE, 2018, 39 (01): : 42 - 49
  • [2] Statins for the primary prevention of cardiovascular disease
    Ebrahim, Shah
    Taylor, Fiona C.
    Brindle, Peter
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [3] Statins for the primary prevention of cardiovascular disease
    Taylor, Fiona
    Huffman, Mark D.
    Macedo, Ana Filipa
    Moore, Theresa H. M.
    Burke, Margaret
    Smith, George Davey
    Ward, Kirsten
    Ebrahim, Shah
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (01):
  • [4] Statins for primary prevention of cardiovascular disease
    Byrne, Paula
    Cullinan, John
    Smith, Susan M.
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
  • [5] Statins for primary prevention of cardiovascular disease
    Otto, Catherine M.
    HEART, 2017, 103 (07) : 477 - 478
  • [6] Statins for primary prevention of cardiovascular disease
    Otto, Catherine M.
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 355
  • [7] Statins and ASS for primary prevention of cardiovascular and cerebrovascular disease
    Goltz, L.
    Bodechtel, U.
    Siepmann, T.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (06) : 283 - 286
  • [8] Evidence-based Use of Statins for Primary Prevention of Cardiovascular Disease
    Minder, C. Michael
    Blaha, Michael J.
    Horne, Aaron
    Michos, Erin D.
    Kaul, Sanjay
    Blumenthal, Roger S.
    AMERICAN JOURNAL OF MEDICINE, 2012, 125 (05) : 440 - 446
  • [9] Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort
    Byrne, Paula
    Cullinan, John
    Gillespie, Paddy
    Perera, Rafael
    Smith, Susan M.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2019, 69 (683) : E373 - E380
  • [10] Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
    Dressel, Alexander
    Fath, Felix
    Kraemer, Bernhard K.
    Klose, Gerald
    Maerz, Winfried
    CLINICAL RESEARCH IN CARDIOLOGY, 2025,